A vision statement on guideline development for respiratory disease: the example of COPD

TY - JOUR

T1 - A vision statement on guideline development for respiratory disease

T2 - the example of COPD

AU - Schünemann, Holger J.

AU - Woodhead, Mark

AU - Anzueto, Antonio

AU - Buist, Sonia

AU - MacNee, William

AU - Rabe, Klaus F.

AU - Heffner, John

N1 - Funding Information: Funding for this conference was made possible (in part) by 1R13HL 90485-01 from the US National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organisations imply endorsement by the US Government. Additional funding was provided by the American Thoracic Society and the European Respiratory Society, and the societies providing travel support for their participating members. The funding sources were provided with a draft of this report for review but had no significant role in the decision about its content. This vision statement has been endorsed by the American Thoracic Society. The programme development committee included the following individuals: Antonio Anzueto, co-chair; Sonia Buist; John Heffner; William MacNee; Klaus Rabe; Holger Schünemann, chair; and Mark Woodhead, co-chair. Funding Information: HJS a member of the GRADE working group and supports the implementation of the GRADE approach worldwide. The GRADE working group is an informal collaboration of people with an interest in developing a common, sensible, and transparent approach to grading quality of evidence and strength of recommendations. Honoraria and consulting fees from for-profit organisations for activities in which the work with GRADE is directly relevant go to support the academic CLARITY research group, of which HJS is a part. He is the documents editor for the American Thoracic Society and senior editor of the American College of Chest Physicians Antithrombotic and Thrombolytic Therapy Guidelines, and both organisations receive income from for-profit organisations. Other institutions or organisations that he is affiliated with probably receive funding from for-profit sponsors that are supporting infrastructure and research that might serve his work. MW has acted as an unpaid scientific adviser to GlaxoSmithKline about a specific research project, and has previously (more than 2 years ago) received payment for travel to meetings and lecture fees from Bayer and Pfizer. ASB has been a member of advisory boards for GlaxoSmithKline, Merck, Pfizer, Sepracor, Novartis, and ALTANA. AA is a member of the GOLD Executive and Scientific committees, and supports the implementation of the GOLD guidelines recommendations. He received honoraria and consulting fees from Bayer-Schering Pharmaceutical, Pfizer, GlaxoSmithKline, Boehringer-Ingelheim, Sepracor, and Schering Plough Corporation. He has been the principal investigator for research grants, and the University of Texas Health Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by Boehringer Ingelheim, Bayer-Schering Pharmaceutical, BARD, Lilly, GlaxoSmithKline, and the US National Institutes of Health. WM has been reimbursed for attending conferences by GlaxoSmithKline, Zambon, and Boehringer Ingelheim, and has received honoraria from GlaxoSmithKline and Zambon for participating as a speaker at various scientific meetings. He also serves on an advisory board for GlaxoSmithKline and as a consultant for Pfizer and SMB Pharmaceuticals. Pfizer funds work carried out in his laboratory by a Clinical Research Fellow. WM also has funding for two multicentre clinical trials, one with Pfizer and one with GSK. KFR is a member of the GOLD Executive and Scientific committees, and supports the implementation of the GOLD guidelines recommendations. He has consulting arrangements with AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Altana, GlaxoSmithKline, and Roche, and has received research support from AstraZeneca, Merck, Altana, and Boehringer Ingelheim. He served on the speakers' bureau for AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Altana, GlaxoSmithKline, and Roche. JH declares that he has no conflict of interest.

PY - 2009

Y1 - 2009

UR - https://www.scopus.com/pages/publications/60649090174

UR - https://www.scopus.com/pages/publications/60649090174#tab=citedBy

U2 - 10.1016/S0140-6736(08)61347-1

DO - 10.1016/S0140-6736(08)61347-1

M3 - Comment/debate

C2 - 18835641

AN - SCOPUS:60649090174

SN - 0140-6736

VL - 373

SP - 774

EP - 779

JO - The Lancet

JF - The Lancet

IS - 9665

ER -